title: Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
authors.forename: George
authors.initials: G
authors.lastname: Papaioannou
authors.forename: Anastasia
authors.initials: A
authors.lastname: Athanasiadou
authors.forename: Georgia
authors.initials: G
authors.lastname: Voutiadou
authors.forename: Maria
authors.initials: M
authors.lastname: Gaitatzi
authors.forename: Ioannis
authors.initials: I
authors.lastname: Batsis
authors.forename: Tasoula
authors.initials: T
authors.lastname: Touloumenidou
authors.forename: Achilles
authors.initials: A
authors.lastname: Anagnostopoulos
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D060965:Clonal Evolution; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate